The development of selective CB₂ receptor agonists is a promising therapeutic approach for the treatment of inflammatory diseases, without CB₁ receptor mediated psychoactive side effects. Preliminary structure-activity relationship studies on pyrazoylidene benzamide agonists revealed the -ylidene benzamide moiety was crucial for functional activity at the CB₂ receptor. A small library of compounds with varying linkage moieties between the pyrazole and substituted phenyl group has culminated in the discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine agonist 19 (CB₂R EC₅₀ = 19 nM, CB₁R EC₅₀ > 10 μM). Docking studies have revealed key structural features of the linkage group that are important for potent functional activity.

选择性CB ₂受体激动剂的开发是一种有希望的治疗炎性疾病的治疗方法，没有CB ₁受体介导的精神活性副作用。对吡唑基苯甲酰胺激动剂的初步结构-活性关系研究表明，亚苄基苯甲酰胺部分对于CB ₂受体的功能活性至关重要。在吡唑和取代的苯基之间具有不同连接部分的小型化合物文库最终发现了有效的选择性吡唑并-[2,3- e ]-[1,2,4]-三嗪激动剂19（CB ₂ R EC ₅₀  = 19 nM，CB ₁ R EC ₅₀ > 10μM）。对接研究已经揭示了该连接基团的关键结构特征，这些特征对于有效的功能活性很重要。